

# CORPORATE FACT SHEET



As of March 31, 2009

## OFFICES

45 Moulton Street  
Cambridge, MA 02138  
e-mail: [info@curis.com](mailto:info@curis.com)  
URL: [www.curis.com](http://www.curis.com)  
Phone: 617-503-6500  
Fax: 617-503-6501

## BUSINESS

Drug Development with a small molecule cancer focus

## FOUNDED

2000

## OWNERSHIP

Publicly traded on the NASDAQ (CRIS)

## SHARES

63,653,698

## EMPLOYEES

Approximately 40

## COLLABORATIONS

- (1) Genentech: Hedgehog Antagonist (Cancer)
- (2) Genentech: Wnt signaling pathway (Cancer)

## TRANSFER AGENT

BNY Mellon Shareowner Services  
P.O. Box 358015  
Pittsburgh, PA 15252-8015  
URL: [www.bnymellon.com/shareowner/isd](http://www.bnymellon.com/shareowner/isd)  
Phone: 877-810-2248

Please see Curis' Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings that we periodically make with the Securities & Exchange Commission for additional information on the company and its status based on filing date.

## MANAGEMENT TEAM

Daniel R. Passeri, President and  
Chief Executive Officer

Michael P. Gray, Chief Operating and  
Chief Financial Officer

Changgeng Qian, Ph.D., M.D., Vice President,  
Discovery and Preclinical Development

Mark W. Noel, Vice President, Technology Management and  
Intellectual Property

## BOARD OF DIRECTORS

James R. McNab, Jr. - Chairman of the Board

Susan B. Bayh

Joseph M. Davie, Ph.D., M.D.

Martyn D. Greenacre

Kenneth I Kaitin, Ph.D.

Daniel R. Passeri

James R. Tobin